Mark Purcell
Stock Analyst at Morgan Stanley
(1.05)
# 3,527
Out of 4,784 analysts
5
Total ratings
50%
Success rate
-9.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $112.57 | +1.27% | 1 | Jan 23, 2024 | |
| SNY Sanofi | Initiates: Equal-Weight | $55 | $55.82 | -1.47% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $38.74 | +13.58% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $73.79 | +15.19% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $69.30 | +73.16% | 1 | Jan 23, 2024 |
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $112.57
Upside: +1.27%
Sanofi
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $55.82
Upside: -1.47%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $38.74
Upside: +13.58%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $73.79
Upside: +15.19%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $69.30
Upside: +73.16%